| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
LSN-3213128 targets AICARFT (aminoimidazole-4-carboxamide ribonucleotide formyltransferase), an enzyme involved in purine biosynthesis. It is a selective, nonclassical antifolate inhibitor with an IC50 of 16 nM.
|
|---|---|
| ln Vitro |
In vitro, LSN-3213128 inhibits AICARFT with an IC50 of 16 nM. Inhibition of AICARFT results in dramatic elevation of 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP) and growth inhibition in NCI-H460 and MDA-MB-231met2 cancer cell lines.
|
| ln Vivo |
In vivo, LSN-3213128 is highly effective in the suppression of tumor growth in a cancer xenograft model. Treatment with this inhibitor in a murine xenograft model of triple negative breast cancer (TNBC) resulted in tumor growth inhibition.
|
| Enzyme Assay |
In vitro enzyme assays measure the inhibition of AICARFT activity using a spectrophotometric or radiometric assay. LSN-3213128 is incubated with purified AICARFT and substrates, and enzyme activity is measured. The IC50 is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays evaluate the antiproliferative effects of LSN-3213128 on cancer cell lines such as NCI-H460 and MDA-MB-231met2. Cells are treated with the compound, and cell viability is assessed. AICARFT inhibition is confirmed by measuring ZMP accumulation.
|
| Animal Protocol |
In vivo animal experiments are conducted in murine xenograft models of cancer, including triple negative breast cancer. LSN-3213128 is administered orally, and tumor growth inhibition is measured.
|
| ADME/Pharmacokinetics |
LSN-3213128 has a molecular formula of C17H16FN3O4S2 and a molecular weight of 409.46. It has a CAS number of 1941211-99-9. The compound is orally bioavailable and soluble in DMSO.
|
| Toxicity/Toxicokinetics |
The toxicity profile of LSN-3213128 is not well documented. As an antifolate, it may have effects on rapidly dividing cells. Standard toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
LSN-3213128 is a research compound with anti-tumor activity. It is a selective, nonclassical, orally bioavailable antifolate that inhibits AICARFT. It is being studied for the treatment of cancer, including triple negative breast cancer.
|
| Molecular Formula |
C17H16FN3O4S2
|
|---|---|
| Molecular Weight |
409.455044746399
|
| Exact Mass |
409.056
|
| CAS # |
1941211-99-9
|
| Related CAS # |
1941211-99-9 (free);1941212-28-7 1941212-29-8 (sodium);
|
| PubChem CID |
121378588
|
| Appearance |
Off-white to pink solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
714
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S1C(=CC=C1N1CC[C@H](C1)O)S(NC1=C(C=C2C=CNC(C2=C1)=O)F)(=O)=O
|
| InChi Key |
N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide
|
| InChi Code |
DSUZLJDXUJUTGI-LLVKDONJSA-N
|
| Chemical Name |
LSN-3213128 LSN 3213128 LSN3213128.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~152.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4422 mL | 12.2112 mL | 24.4224 mL | |
| 5 mM | 0.4884 mL | 2.4422 mL | 4.8845 mL | |
| 10 mM | 0.2442 mL | 1.2211 mL | 2.4422 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
